Review

Unveiling of cannabidiol in the treatment of rare childhood epilepsies: Dravet and Lennox Gastaut syndromes

Mahabba N. Eldernawi, Fadia M. Gafri*
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, University of Tripoli, Tripoli, Libya

*Corresponding author: F.gafri@uot.edu.ly
https://orcid.org/000-0002-9261-2041

Received: 28-02-2022, **Revised:** 23-05-2022, **Accepted:** 28-05-2022, **Published:** 30-06-2022

HOW TO CITE THIS
Eldernawi MN and Gafri FM (2022) Unveiling of cannabidiol in the treatment of rare childhood epilepsies: Dravet and Lennox Gastaut syndromes. Mediterr J Pharm Pharm Sci. 2 (2): 18 - 31. https://doi.org/10.5281/zenodo.6780458.

Keywords: Antiepileptic drug, cannabidiol, Dravet syndrome, Lennox Gastaut syndrome, mechanism of action, treatment resistant epilepsies

Abstract: In childhood, epilepsy is the most common globally widespread neurological problem, usually with serious consequences for this most critical period of development. Dravet and Lennox Gastaut syndromes are two forms of rare and severe treatment resistant epilepsies that occur early in the life. These resistant epilepsies recognised by continuous unrelenting seizures of many types including the occurrence of status epilepticus. In addition, it is associated with the development of behavioural, neurological, cognitive deficits and the sequelae of increased risk of mortality rate. Historically, cannabis was found to possess several medical benefits including its use for epilepsy. In this review, information and data were extracted from 99 references using PubMed and Google Scholar (November, 2021). Data with clinical evidence on cannabidiol regarding its efficacy on Dravet syndrome and Lennox Gastaut syndrome, mechanism of action, safety, pharmacokinetic properties and interactions with anti-epileptic medications were all reviewed and discussed. Highly purified cannabidiol is a cannabis derived compound that is suggested in recent research as an add-on therapy to the existing treatment of both resistant epileptic types; since it is able to reduce the duration, frequency and severity of seizure disorders. It is also characterised with multiple signalling transduction mechanisms, primarily via inhibition of excitatory and potentiation of inhibitory pathways.

Introduction

Epilepsy is the commonest neurological problem affecting over 60 million people around the world. In terms of incidence, the average GP will have between six and eight severely mentally handicapped patients in the practice, of whom between one and three will be children or adolescents with a seizure disorder. Epilepsy is categorized by recurrent seizures which are fleeting episodes of involuntary movements that may be a partial (involving a part of the body) or a generalised (involving the entire body) [1]. Unfortunately, around one third of patients do not respond to any of the current antiepileptic drugs [2]. Epilepsy is a chronic non-communicable network disorder of the central nervous system; involving many complex underlying mechanisms and potential factors that influence the occurrence of this disease. It is driven by epigenetic dysregulation; elemental changes of cellular function which arise as a consequence of change in

gene expression and its regulation [3]. Epilepsy is characterised by two or more seizure incidences [4], excessive electrical discharges originating from cerebral neurons displaying as distinct behavioural and motor activity creating an alteration of consciousness [5]. Some seizure disorders cease or improve during puberty, some persist, some become worse and some change. Thus, the goal of this review is to highlight the use of the newly approved drug compound cannabidiol (CBD) for the treatment of childhood rare drug resistant epilepsies. It will dive through the origins and nature of this compound, the characteristics of these epileptic conditions and will demonstrate why CBD is beneficial to these conditions. By showing the pharmacological evidence collected from scientific literature supporting this area.

The aetiology of epilepsy: In general, epilepsy aetiologies are variable in different age groups and geographical areas. Epilepsies of childhood, adolescence and young adults are usually associated with congenital, developmental and genetic conditions. However, in elderly people; the most common causes are cerebrovascular diseases, central nervous system infections and tumours [6].

Selecting the appropriate therapy: Once the diagnosis of epilepsy in children is made, a seizure preventing medication is prescribed. The selection of appropriate therapy therefore is based on a confirmed diagnosis, plus an accurate identification of the type of seizure disorder. Initial medication should consist of monotherapy, weighing possible side effects of anticonvulsant therapy against the expected benefits to the patient [7]. If the medication is unsuccessful, other management options arise; including surgery [8] (usually removal of tumour or malformed blood vessels), vagal nerve stimulation [9]. In addition, complementary therapy and a special diet that is known as the ketogenic diet in which high amounts of fat and low amounts of carbohydrates are consumed [10].

Antiepileptic drugs: The decision to treat seizures with antiepileptic drugs is a major event in a young person's life. It may be the final confirmation of the diagnosis of epilepsy, it may mean regular medication for long periods, and may have serious medical, psychological and social impacts. Antiepileptic drugs (AEDs) are considered the first line for treatment of epilepsy. They are introduced early on, in order to prevent seizures [11]. These medications interact with neurotransmitter receptors and ion channels thereby decreasing membrane excitability [12], either by inhibiting excitatory mechanisms or potentiation of inhibitory mechanisms. For instance, carbamazepine, felbamate and topiramate block the excitatory voltage gated sodium channels [13]. However, voltage gated calcium channels are blocked by ethosuximide and lamotrigine. But, calcium channel $\alpha_{2\text{-}\delta}$ subunit is modulated by gabapentin and pregabalin [14]. In the mammalian brain, the main inhibitory and excitatory neurotransmitters mediating synaptic transmissions are amino acids gamma-aminobutyric acid (GABA) and glutamate, respectively [15]. It has been recognised that GABA can be potentiated by barbiturates, diazepam, felbamate, stiripentol, topiramate and valproate [16]. Whereas felbamate, lamotrigine and topiramate antagonise the excitatory glutamate receptors [17].

Epidemiology of epilepsy in childhood: Epidemiological studies provide information on the prevalence, incidence, causal factors and natural history of epilepsy in childhood, but rates vary depending on the way in which epilepsy is defined, on the completeness of case-finding and on the populations studied. It is well recognized that the rate of epilepsy found in child population studies varies according to the definition used. The rates varying from 1.5 to 150 per 1 000 children. It is not possible to obtain information on the natural history of epilepsy or fits in children from cross-sectional studies. Some longitudinal studies, which follow children over a period of time, are required. However, it is difficult to tell whether the epidemiology of epilepsy is changing over time because of the different definitions and different populations studied. According to the published data, epilepsy is of the most common neurological disease affecting about 1% of children, the incidence of it being 5 - 7 cases per 10 000 children

from birth to age fifteen [18]. Amongst several childhood epilepsies; Dravet syndrome (DS) and Lennox Gastaut syndrome (LGS) are forms of rare, worse and severe treatment resistant epilepsies (TRE) that occur early in life. Each of these syndromes is classified as epileptic encephalopathy disorder; in which unrelenting and continual epileptic activity occurs. Thus, eliciting cognitive and behavioural defects that may develop over time into progressive cerebral dysfunction [19].

Dravet Syndrome: Dravet syndrome has previously been known as severe myoclonic epilepsy of infancy (SMEI) and was first described by Dravet in 1978 [20]. In all the cases of DS, seizures begin within the first year of life with an estimated prevalence of 0.5 to 1 per 20 000 new-borns [21]. The onset being usually between 5 and 8 months of age accompanied by frequent febrile unilateral clonic convulsions and sometimes non-febrile seizures could be present. These early DS seizures are typically prolonged and correlated to fever or infection. After this stage, seizures of multiple types emerge (myoclonic, atypical absences and complex focal seizures) which habitually advance to status epilepticus (SE) and associated severe psychomotor deterioration. The persistent progression stops at about 10 years of age with a decline in seizure frequency although abiding neurologic sequelae [22]. Seizure stimulants besides fever, infectious illnesses [23] or vaccinations [21], also include elevated body temperature (maybe by hot bath water) and photic (light) or pattern stimulation [23]. Unfavourably, in most cases the prognosis of DS is poor; seizures become intractable and resistant to drugs. Further, cognitive and motor impairment pan out in all cases and the mortality rate is notably high [23].

Genetic predisposition in Dravet syndrome: Dravet syndrome is described as a genetic disease, due to a voltage-gated sodium channel alpha subunit 1 *SCN1A* gene mutation (haploinsufficiency) [24]. Mutations in this gene were found in 67% to 86% of patients from larger studies as described by Charlotte Dravet and colleagues [23]. Although, the majority of mutations occur de novo and inherited cases are depicted [25]. As for genetics, family history of epilepsy is also frequent in many of the cases. These mutations are found in other forms of epilepsy, non-epileptic disorders and febrile seizures [26]. The spectrum of *SCN1A* disorders extents from mild familial hemiplegic migraines to febrile seizures, generalised epilepsy with febrile seizures, intractable childhood epilepsy with generalised tonic - clonic seizures to DS being the most severe form [27].

Lennox Gastaut syndrome: In parallel to DS, LGS primarily labelled as "Petit mal variant" by Lennox in 1966 [28] is likewise a childhood onset of severe rare epileptic encephalopathy contributing to intellectual and developmental disabilities. It has prevalence rate of 1 - 10% of all childhood epilepsies [29] but more predominant in males [30]. It is first diagnosed between the ages of three and eight years [31], though a few studies reported 10 - 16% of LGS cases have late onset (over eight years) [32, 33]. This condition characterised by multiple seizures, most commonly tonic-clonic seizures. Patients of LGS suffer through at least one episode of SE in their history usually following tonic, atonic and myoclonic seizures as well as immobilizing seizures known as "falls" or "epileptic drop attacks" [30]. Due to these drop attacks, patients with LGS are continuously prone to be injured, they have to physically protect themselves by using helmets and remain in wheelchairs [34]. This not only affects their health related quality of life (HRQL) but also impacts their caregivers [35].

Causes of Lennox Gastaut syndrome: Lennox Gastaut cases can be either cryptogenic (de novo) or from aetiological causes as a cortical dysplasia, perinatal hypoxia, congenital infections, central nervous system infections such as encephalitis and meningitis [36].

Mortality rate of Dravet syndrome and Lennox Gastaut syndrome: Mortality rate in DS and LGS syndromes is higher than other rates found in general population of epilepsy patients. In DS, for instance, the mortality rate ranges from 5 to 20% [37], most commonly due to sudden unexpected death in epilepsy (SUDEP) occurring during sleep.

It has been marked with the highest SUDEP rate 9.32 per 1 000 person yearly, higher than the latest 5.1 SUDEP rate per 1 000 person yearly for adults with refractory epilepsy. Furthermore, the elevated mortality rate could be a result of SE and its subsequent complications [38]. On the other hand, LGS has a lower mortality rate ranging from 3 to 7% usually resulting from seizure accidents and injuries [36].

Treatment of Dravet syndrome and Lennox Gastaut syndrome: Antiepileptic drugs provide little to no relief from seizures in treatment of resistant epilepsies. In such syndromes, as complete seizure cessation is highly unachievable; the main aim of the treatment is to reduce and limit either seizure occurrence or frequency, control symptoms, decrease co-morbidities and neurological sequelae [39]. In case of DS, the first line of treatment include valproate and clobazam but are inadequate as therapeutic options when used on their own [40]. As a consequence, an alternative second line and adjunctive therapy should be used as topiramate [41] and stiripentol [42]. Similarly, the first line of treatment mainly used in LGS are valproate and clobazam [39] as well as lamotrigin [43]. Since LGS is also treatment resistant, add-on therapy is typically indicated and proven to be beneficial. Some adjunctive therapies used are topiramate, felbamate, rufinamide and fenfluramine [44, 45]. What makes the treatment in both syndromes peculiar? it is the fact that many of the generally well-known antiepileptic drugs are actually found to cause seizure exacerbation. Either those used in DS (carbamazepine, phenytoin, lamotrigine [46], oxcarbazepine [47], phenobarbital and others) [48] or in LGS (carbamazepine, phenytoin, vigabatrin) [30, 49] (**Table 1**). Last but not least, a novel drug known as cannabidiol has recently emerged as a new hope for the treatment of DS and LGS.

Table 1: Antiepileptic drugs in treatment of Dravet and Lennox Gastaut syndromes

Treatment resistant epilepsy	First line	Second line Adjunctive	Causing seizure exacerbation	Novel drug
Dravet syndrome	Valproate Clobazam [40]	Stiripentol Topiramate [41, 42]	Phenytoin Carbamazepine Lamotrigine [46] Oxacarbazepine [47] Phenobarbital [48]	Cannabidiol
Lennox Gastaut syndrome	Valproate Clobazam [39] Lamotrigine [43]	Topiramate Felbamate Rufinamide Fenfluramine [44, 45]	Carbamazepine Phenytoin Vigabatrin [30, 49]	

Medical history and drug profile of Cannabis: Cannabis (*Cannabis sativa*, *Cannabis indica*, hashish, hemp and marijuana) is one of the oldest cultivated plants around the world. The world cannabis refers to all products derived from the plant *cannabis sativa*. Its medical use and multiple indications were first recorded in the world's oldest pharmacopeia of ancient China in 2700 BC [50]. Then it was introduced in India, as an analgesic, anticonvulsant and a tranquilizer amongst its many recognised uses around 1 000 years BC [51]. In 1 464 AD, the Arab historian Ibn Al-Badri reported that the caliph's chamberlain's epileptic son was given "hashish" as medication and that it had completely cured him but also caused him to be in a state of addiction [52]. Later on, the modern use of cannabis was common in the Western world in the years of the 1800s, its therapeutic uses were introduced by Irish physician William O'shaug-hnessy as he was one of the first scientists to publish papers on this topic [53]. In the same era, Queen Victoria had used cannabis to alleviate her

menstrual symptoms. According to cannabis history review by Crocq 2020, CBD was isolated from the plant for the first time in 1940 by Illinois university team, however, its structure has been elucidated in 1963 [54]. In the wake of the development of modern medicaments, cannabis' medical use notably declined and it was not until the second half of the 20th century that it intrigued interest in the scientific world [51].

A decade later, cannabis was perceived as dangerous in 1970 when it was placed amongst heroin, LSD (Lysergic acid diethylamide) and MDMA (3, 4-Methylenedioxymethamphetamine) in the classification of schedule 1 drugs [54]. After the cannabinoid receptors were discovered in the human body, the medical uses of CBD were further explored [54] that led to the legalisation of cannabis in some parts of the world in the 2000s [55]. This history of cannabis in medical use was summarized in **Figure 1**. In June 2018, a pharmaceutical drug (oral solution) known as Epidiolex® (GW Pharmaceuticals, Cambridge, UK) was approved by Food and Drug Administration (US FDA) as the first and only drug consisting solely of highly purified cannabidiol (CBD) for the treatment of DS and LGS [56]. Lately, in September 2019, this drug gained the marketing authorisation approval by the European Commission (EC) for patients with DS and LGS aged 2 years and more [57].

Figure 1: Timeline of medical cannabis



CBD: Cannabidiol, CBD1 and CBD2: Cannabinoid receptors 1 and 2, LSD; Lysergic acid diethylamide, MDMA: 3,4-methylenedioxy-methamphetamine.

Cannabidiol

So far, more than 540 natural compounds of diverse chemical classes were discovered to contribute to the peculiar pharmacological characteristics of the cannabis plant [57]. Of the compounds are 113 identified cannabinoids [59]. Cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) are the most prevalently studied. These two compounds are found in variable concentrations depending on the genus of the cannabis plant [60]. The major psychoactive cannabinoid THC, is proven to hold anti-inflammatory, anti-emetic, appetite-stimulant and analgesic properties [61]. On the contrary, CBD or "2-[(6R)-6-Isopropenyl 3-methyl-2-cyclohexen-1-yl]-5-pentyl-1,3-benzene-diol" as in, **Table 2**, is a completely non-psychoactive agent [62] that has demonstrated remarkable medical benefit in epilepsy [63], anxiety [64], cancer, diabetes, as well as neuroprotection and reduction of tobacco dependence [58]. CBD is found in multiple approved medical formulations, for example Epidiolex® [65] and Sativex® [66] (**Table 3**).

Table 2: Chemical name, structure and molecular formula of cannabidiol [62]

Chemical name	Structure	Molecular formula
Cannabidiol (CBD) 2-[(6R)-6-Isopropenyl3-methyl-2-cyclohexen-1-yl]-5-pentyl-1,3-benzene-diol		$C_{21}H_{30}O_2$

Table 3: FDA approved drugs containing cannabidiol [65, 66]

Drug	Active ingredient	Dosage form	Indication
Epidiolex®	Cannabidiol	Oral solution	Lennox Gastaut syndrome, Dravet syndrome, Tuberous sclerosis complex
Sativex® (nabiximols)	delta-9-tetrahydr-ocannabinol, cannabidiol	Oromucosal spray	Multiple sclerosis

Pre-clinical trials: By 2018, many trials were carried out, investigating the effects of CBD on seizure models. It is found to be effective in acute seizures for rodents, following intraperitoneal administration [67]. In other study, CBD also prevented the tonic convulsions that are induced by convulsant drugs or electrical currents. Moreover, differential effects were simultaneously examined and findings suggested that CBD does in fact inhibit the seizure spread in the central nervous system through GABA but not glycine mechanisms [68]. In pre-clinical *in-vivo* studies of DS model, cannabidiol was tested on *SCN1A+/−* mice; because these well-defined phenocopy of human DS. They present thermally induced, spontaneous seizures besides autism-like traits (autistic like social deficits). After treatment with CBD (100 mg/kg), a reduction in the spontaneous seizure rate by 70% was noted. It is significantly reduced the frequency, duration, severity of seizure (spontaneous and febrile), and improved the social interaction behaviours of DS mice. In fact, DS mice are hyperactive compared to the wild type. In an open field test for locomotor activity, treating DS mice with 100 mg/kg CBD considerably reduced their distance travelled [68]. Upon chronic administration of CBD in a recent animal study of DS, premature mortality was reduced. Furthermore, it was observed that the social behaviour as well as the memory function of mice had improved [24].

Clinical trials: Following the pre-clinical studies, many clinical trials were performed for the efficacy of CBD on patients with DS and LGS. There are different studies conducted including randomized double-blind clinical trials, multinational randomized double-blind clinical trials, double-blind placebo-controlled randomized clinical trials, retrospective clinical studies and open label extension studies. All of these trials were similar in the outcome and main findings, as the administration of CBD resulted in a decrease of overall seizures, ranging from 43% to 57% reduction. Generally, most patients who used cannabidiol experienced an improvement in their seizure symptoms and frequencies and some even became seizure free (about 5% in a trial). These clinical trials are summarised in **Table 4** [70, 71 - 74].

Table 4: Clinical trial of cannabidiol for Dravet and Lennox Gastaut syndromes

Syndrome	Type of study	Key points	References
Dravet syndrome	Randomized double-blind clinical trial	Convulsive seizure frequency compared with baseline was reduced by 48.7% in the 10 mg/kg/d cannabidiol group and 45.7% in the 20 mg/kg/d cannabidiol group	Miller et al. [70]
	Multinational, randomized, double-blind trial	Treatment with cannabidiol BD (20 mg/kg): - About 43% of patients had at least a 50% reduction in convulsive-seizure frequency - 5% of patients became seizure-free	Devinsky et al. [71]
	Retrospective clinical study	Administration of CBD showed more than 50% reduction of seizure frequency in 30%	Koo et al. [72]
Lennox Gastaut syndrome	Double-blind, placebo-controlled, randomized clinical trial	Addition of CBD at a dose of 10 mg or 20 mg/kg per day to a conventional antiepileptic regimen resulted in greater reductions in the frequency of drop seizures by 37.2% and 41.9%, respectively)	Devinsky et al. [73]
	Open-label extension (OLE) study	An interim analysis reported: - Median reduction in monthly total seizure frequency ranged from 48% to 57% - 88% of patients/caregivers reported an improvement in the patient's overall condition	Thiele et al. [74]
	Retrospective clinical study	Cannabidiol administration showed an overall reduction of seizure frequency in the Lennox Gastaut group was 52.9%	Koo et al. [72]

Proposed mechanisms of action of CBD: Although the exact mechanism of cannabidiol has not yet been fully understood, CBD is known as a "multi-target drug" [75], since it interacts with several endocannabinoid and non-endocannabinoid signalling systems, having multimodal mechanisms of actions (**Figure 2**). For instance, CBD can work as a partial agonist on dopamine-D_2 [76] and serotonin $5HT_{1A}$ receptors [77]. Whereas, it is an agonist of transient receptor potential (TRP) cation channels, specifically activating and acting as an agonist on TRP vanilloid receptor-1 channel (TRPV1), as well as transient receptor potential vanilloid 2 (TRPV2) and the ankyrin-1 transient receptor potential channel (TRPA1) resulting in decreased calcium levels and intrinsic neuronal excitability [78, 79]. The most well-known mechanism of CBD is the activation of the endocannabinoid system through the modulation of G protein coupled cannabinoid receptors CB1 and CB2 [80]. CBD inhibits fatty acid amide hydrolase (FAAH) which results in the raising of anandamide levels due to the blockage of the re-uptake and breakdown of anandamide; a lipid mediator that acts as an endogenous ligand of the CB receptors [81]. Consequently, stimulation of cannabinoid receptors suppresses the pre-synaptic release of multiple neurotransmitters such as GABA, glutamate, acetylcholine, serotonin and noradrenaline [82]. CBD also inhibits the reuptake of adenosine, therefore, increasing adenosine extracellular levels and activating adenosine receptors [83]. Specifically, activates pre-synaptic A1 receptors, thus the reduction of glutamate release from excitatory terminals [84]. In recent studies, CBD has been indicated to influence and regulate gene expression through the activation of the nuclear peroxisome proliferator-activated receptor gamma (PPARγ). Parallel, the neuro-protection that CBD provides is attributed to the

activation of adenosine receptors [83], PPARγ and 5-HT1A receptors [85]. Another putative novel orphan G protein coupled receptor 55 (GPR55) was identified as new promising target for cannabidiol. It is localised in axon terminals and by which presynaptic calcium ions are elevated thereby facilitating glutamate release. Therefore, CBD acts as an antagonist to GPR55 receptor, causing a reduction in glutamate exocytosis, as a deduction lowering neuronal excitation [84, 86]. Additional mechanisms that could explain the role of cannabidiol in epilepsy are the inhibitory effects of voltage dependent sodium channels [87] and the allosteric modulation of (δ) delta-opioid receptors [88]. These mechanisms altogether reduce neuro-excitability and vesicular release; in turn decreasing excitatory neurotransmission leading to a decline in seizure activity.

Figure 2: Multimodal signalling mechanism of actions of cannabidiol



A_1: Adenosine receptor, CB1: cannabinoid receptor 1, CB2: cannabinoid receptor 2, FAAH: fatty acid amide hydrolase, GPR55: G protein coupled receptor 55, 5-HT_{1A}: 5-hydroxytryptamine 1 subtype A receptor, PPARγ: peroxisome proliferator-activated receptor gamma, TRPA1: transient receptor potential ankyrin 1, TRPM8: Transient receptor potential cation channel subfamily M (melastatin), TRPV1: transient receptor potential vanilloid receptor 1 channel, TRPV2: transient receptor potential vanilloid receptor 2 channel.

Pharmacokinetic aspects of cannabidiol: Epidiolex®, as mentioned, is the first approved medication purely containing CBD. It is an oral solution with the concentration of 100 mg/ml. The absorption of CBD following an oral administration is slow and irregular. CBD has pharmacological effects with an onset time of 30 to 60 minutes, which most likely would be contributed to the lipophilic nature of the drug and its low water solubility (12.6 mg per L) [84, 89]. The bioavailability of CBD lasts for about eight hours, reaching a peak after 2 - 4 hours. An advantage of CBD as medication, is that even though it has a half-life of 1.4 - 10.9 hours, the half-life extends to 2 - 5 days with repeated oral administration [89]. CBD is extensively and rapidly distributed in most vital organs including the lungs, liver, heart, brain and in the hypo-vascularized tissues [90]. Its concentration in the plasma and brain elevate in a dose dependent manner, mainly following high fat meals due to its lipophilicity [89]. The metabolism of CBD in humans takes place entirely in the liver by liver cytochrome enzymes (CYP2C19 and CYP3A4). About 75% of CBD is removed by hepatic metabolism prior to reaching the systemic circulation. It is reported to be excreted unchanged in the faeces [90].

Medical cannabidiol drug interactions, adverse effects and safety: The most important interactions

that may occur with CBD are with other antiepileptic drugs, especially ones that concomitantly interact with liver enzymes. As stated above, CBD undergoes metabolism through cytochrome enzymes present in the liver. This is also the case for other AEDs such as phenobarbital, phenytoin and stiripentol; as well as drugs either inducing or inhibiting CYP2C19 metabolism as oxcarbazepine, felbamate and topiramate [91]. In conditions like DS and LGS, multiple drugs are commonly used. Thereby, checking of liver function tests (LFTs) and serum concentrations of AEDs must be done continuously. In open label safety study, the pharmacokinetic interactions of AEDs were determined. In patients taking valproate with CBD simultaneously, the LFT results were found to be abnormal and significantly high. However, serum levels were remarkably changed for drugs when used with escalated doses of CBD such as that seen in decreased clobazam, while increased rufinamide and topiramate levels [92]. Hence, dosage adjustments should be made accordingly with each patient individually depending upon which medications and dosages are taken.

Cannabidiol has an overall good safety profile. Generally well tolerated, especially when it is compared with other AEDs that have more distressing side effects [93]. The most common adverse events noted in patients taking the drug CBD/Epidiolex® included gastrointestinal discomfort and disturbances such as diarrhoea, nausea and vomiting [94]. This may be a result of the irregular and low solubilisation of CBD in gastrointestinal tract as it is hydrophilic environment [89]. Also, loss of weight is an untoward effect caused by CBD [95]; although it not being a serious side effect, it is important to some degree especially for children in the stages of growth. Somnolence, sedation and fatigue were another side effects resulted in patients of DS and LGS taking CBD/Epidiolex® [94]. Furthermore, somnolence and elevations in serum aminotransferases were precipitated by concomitant AEDs therapy such as clobazam [96] and valproate [97]. Nevertheless, many of these mentioned side effects are not considered serious and can be avoided by giving individual dosage adjustments.

Conclusion: Overall, not only does CBD reduce seizures by 50%, but it is also reported that patients taking it noticed an improvement in their health related quality of life (HRQL). This was emphasized by caregivers through the Caregiver Global Impression of Change scoring, a drastic and significant improvement was noted in the overall condition of the children who took CBD/Epidiolex® for treatment of DS [98]. It is important that AEDs are assessed on their efficiency of reduction of seizures, reduction of seizure frequencies, reaching seizure-free days and improving the HRQL of patients. Hence, CBD represents a good choice of medication in DS and LGS. However, CBD is a novel drug for epilepsy, so it is still not legal worldwide, which limits its use. Due to it being a cannabis based medication, there is a stigma surrounding it. This making its medical use controversial socially and religiously; thus hinders the hopeful outcomes of the medication that could be seen otherwise. Another downside to the available CBD /Epidiolex® is its cost [98] which makes it highly inaccessible for most patients. Ultimately, there is a huge excitement regarding the future prospects of CBD.

Conflict of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author contributions: Both authors substantially contributed to the conception, compilation of data, checking and approving the final version of the manuscript.

Ethical issues: Including plagiarism, informed consent, data fabrication or falsification and double publication or submission have completely been observed by authors.

References

1. Epilepsy (2021) WHO fact sheets. https://www.who.int/news-room/fact-sheets/detail/epilepsy. Accessed November 20, 2021.
2. Janmohamed M, Brodie MJ, Kwan P (2020) Pharmacoresistance - epidemiology, mechanisms, and impact on epilepsy treatment. Neuropharmacology. 168: 107790. doi.org/10.1016/j.neuropharm.2019.107790.
3. Qureshi IA, Mehler MF (2010) Epigenetic mechanisms underlying human epileptic disorders and the process of epileptogenesis. Neurobiology of Disease. 39 (1): 53-60. doi.org/10.1016/j.nbd.2010.02.005.
4. Thomson DC (1971) The Johns Hopkins University. The American review of Canadian studies. 1 (2): 49-52. doi.org/10.1080/02722017109481317.
5. Friedman MJ, Sharieff GQ (2006) Seizures in children. Pediatric Clinics of North America. 53 (2): 257-277. doi.org/10.1016/j.pcl.2005.09.010.
6. Sander JW, Shorvon SD (1996) Epidemiology of the epilepsies. Journal of Neurology Neurosurgery and Psychiatry. 61 (5): 433-443. doi.org/10.1136/jnnp.61.5.433.
7. Bengleil M, Alzunni F, Shaboun S, Almiahuob M (2022) Hematological consequences of antiepileptic drug therapy among children with epilepsy. Mediterranean Journal of Pharmacy and Pharmaceutical Sciences. 2 (1): 46-54. doi.org/10.5281/zenodo.6399498.
8. Smith D, Chadwick D (2001) The management of epilepsy. Neurology in practice. Journal of Neurology Neurosurgery and Psychiatry. 70 (IIS): ii15-ii21. doi.org/10.1136/jnnp.70.suppl_2.ii15.
9. Uthman BM, Reichl AM, Dean JC, Eisenschenk S, Gilmore R, Reid S, Roper SN, Wilder BJ (2004) Effectiveness of vagus nerve stimulation in epilepsy patients: a 12-year observation. Neurology. 63 (6): 1124-1126. doi.org/10.1212/01.WNL.0000138499.87068.
10. Ułamek-Kozioł M, Czuczwar SJ, Januszewski S, Pluta R (2019) Ketogenic diet and epilepsy. Nutrients. 11 (10): E2510. doi.org/10.3390/nu11102510.
11. Sankaraneni R, Lachhwani D (2015) Antiepileptic drugs - a review. Pediatric Annals. 44 (2): e36-42. doi.org/10.3928/00904481-20150203-10.
12. Macdonald RL, Kelly KM (1993) Antiepileptic drug mechanisms of action. Epilepsia. 34 (S5): S1-S8. doi.org/10.1111/j.1528-1157.1993.tb05918.x.
13. Sills G, Rogawski M (2020) Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 15 (168): 107966. doi.org/ 10.1016/j.neuropharm.2020.107966.
14. Rogawski MA, Taylor CP (2006) Calcium channel α2-δ Subunit, a new antiepileptic drug target. Epilepsy Resarch. 69 (3): 183-272. doi.org/10.1016/j.eplepsyres.2006.03.014.
15. Goldenberg MM (2010) Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. PT: a peer-reviewed journal for formulary management. 35 (7): 392-415. PMID:20689626.
16. Jembrek MJ, Vlainic J (2015) GABA Receptors: pharmacological potential and pitfalls. Current Pharmaceutical Design. 21 (34): 4943-4959. doi.org/10.2174/1381612821666150914121624.
17. Meldrum BS (1996) Update on the mechanism of action of antiepileptic drugs. Epilepsia. 37 (6S): S4-S11. doi.org/10.1111/j.1528-1157.1996.tb06038.x.
18. Cowan LD (2002) The epidemiology of the epilepsies in children. Mental Retardation and Developmental Disabilities Research Reviews. 8 (3): 171-181. doi.org/10.1002/mrdd.1003.
19. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshé SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 51 (4): 676-685. doi.org/10.1111/j.1528-1167.2010.02522.x.
20. Millichap JJ, Koh S, Laux LC, Nordli DR Jr (2009) Child neurology: Dravet syndrome: when to suspect the diagnosis. Neurology. 73 (13): e59-62. doi.org/10.1212/WNL.0b013e3181b9c880.
21. Muthugovindan D, Hartman AL (2010) Pediatric epilepsy syndromes. The Neurologist. 16 (4): 223-237. doi: 10.1097/NRL.0b013e3181d9d6b7.
22. Dravet C (2011) The core Dravet syndrome phenotype. Epilepsia. 52 (2S): 3-9. doi.org/10.1111/j.1528-1167.2011.02994.x.
23. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O (2005) Severe myoclonic epilepsy in infancy: dravet syndrome. Advances in Neurology. 95: 71-102. doi.org/10.1201/b13560-21.

24. Patra PH, Serafeimidou-Pouliou E, Bazelot M, Whalley BJ, Williams CM, McNeish AJ (2020) Cannabidiol improves survival and behavioural co-morbidities of Dravet syndrome in mice. British Journal of Pharmacology. 177 (12): 2779-2792. doi.org/10.1111/bph.15003.
25. Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P (2001) De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. American Journal of Human Genetics. 68 (6): 1327-1332. doi.org/10.1086/320609.
26. Harkin LA, McMahon JM, Iona X, Dibbens L, Pelekanos JT, Zuberi SM, Sadleir LG, Andermann E, Gill D, Farrell K, Connolly M, Stanley T, Harbord M, Andermann F, Wang J, Batish SD, Jones JG, Seltzer WK, Gardner A, Infantile Epileptic Encephalopathy Referral Consortium, Sutherland G, Berkovic SF, Mulley JC, Scheffer IE (2007) The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain. 130 (3): 843-852. doi.org/10.1093/brain/awm002.
27. Depienne C, Trouillard O, Saint-Martin C, Gourfinkel-An I, Bouteiller D, Carpentier W, Keren B, Abert B, Gautier A, Baulac S, Arzimanoglou A, Cazeneuve C, Nabbout R, LeGuern E (2009) Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. Journal of Medical Genetics. 46 (3): 183-191. doi.org/10.1136/jmg.2008.062323.
28. Gastraut H, Roger J, Soulayrol R, Tassinari CA, Régis H, Dravet C, Bernard R, Pinsard N, Saint-Jean M (1966) Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as “petit mal variant”) or Lennox syndrome. Epilepsia. 7 (2): 139-179. doi.org/10.1111/j.1528-1167.1966.tb06263.x.
29. Asadi-Pooya AA (2018) Lennox-Gastaut syndrome: a comprehensive review. Neurological Sciences. 39 (3): 403-414. doi.org/10.1007/s10072-017-3188-y.
30. van Rijckevorsel K (2008) Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatric Disease and Treatment. 4 (6): 1001-1019. doi.org/10.2147/NDT.S1668.
31. Camfield PR (2011) Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 52 (5S): 3-9. doi.org/10.1111/j.1528-1167.2011.03177.x.
32. Asadi-Pooya AA, Sharifzade M (2012) Lennox-Gastaut syndrome in south Iran: electro-clinical manifestations. Seizure. 21 (10): 760-763. doi.org/10.1016/j.seizure.2012.08.003.
33. Goldsmith IL, Zupanc ML, Buchhalter JR (2000) Long-term seizure outcome in 74 patients with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in defining the cryptogenic subgroup. Epilepsia. 41 (4): 395-399. doi.org/10.1111/j.1528-1157.2000.tb00179.x.
34. Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A (2017) Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Frontiers in Neurology. 8: 505. doi.org/10.3389/fneur.2017.00505.
35. Gallop K, Wild D, Nixon A, Verdian L, Cramer JA (2009) Impact of Lennox-Gastaut syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review. Seizure. 18 (8): 554-558. doi.org/10.1016/j.seizure.2009.06.005.
36. Amrutkar C, Riel-Romero RM (2020) Lennox Gastaut syndrome. [Updated 2021 Aug 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 30422560.
37. Sakauchi M, Oguni H, Kato I, Osawa M, Hirose S, Kaneko S, Takahashi Y, Takayama R, Fujiwara T (2011) Mortality in Dravet syndrome: search for risk factors in Japanese patients. Epilepsia. 52 (2S): 50-54. doi.org/10.1111/j.1528-1167.2011.03002.x.
38. Cooper MS, Mcintosh A, Crompton DE, McMahon JM, Schneider A, Farrell K, Ganesan V, Gill D, Kivity S, Lerman-Sagie T, McLellan A, Pelekanos J, Ramesh V, Sadleir L, Wirrell E, Scheffer IE (2016) Mortality in Dravet syndrome. Epilepsy Research. 128: 43-47. doi.org/10.1016/j.eplepsyres.2016.10.006.
39. Wirrell EC (2016) Treatment of Dravet syndrome. Canadian Journal of Neurological Sciences. 43 (S3): S13-S18. doi.org/10.1017/cjn.2016.249.
40. Chiron C (2011) Current therapeutic procedures in Dravet syndrome. Developmental Medicine and Child Neurology. 53 (2S): 16-18. doi.org/10.1111/j.1469-8749.2011.03967.x.
41. Stiripentol (Diacomit): For severe myoclonic epilepsy in infancy (Dravet syndrome) (2015) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. PMID: 26962599.
42. Chiron C (2014) Stiripentol for the treatment of Dravet syndrome. Orphan Drugs: Research and Reviews. 4: 29-38. doi.org/10.2147/ODRR.S47619.

43. Strzelczyk A, Schubert-Bast S (2021) Expanding the treatment landscape for Lennox-Gastaut syndrome: current and future strategies. CNS Drugs. 35 (1): 61-83. doi.org/10.1007/s40263-020-00784-8PMID:33479851.
44. Auvin S (2020) Lennox-Gastaut syndrome: new treatments and treatments under investigation. Revue Neurologique (Paris). 176 (6): 444-447. doi.org/10.1016/j.neurol.2020.01.364PMID:32409177.
45. Balagura G, Cacciatore M, Grasso EA, Striano P, Verrotti A (2020) Fenfluramine for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. CNS Drugs. 34 (10): 1001-1007. doi.org/10.1007/s40263-020-00755-z.
46. Ragona F, Granata T, Dalla Bernardina B, Offredi F, Darra F, Battaglia D, Morbi M, Brazzo D, Cappelletti S, Chieffo D, De Giorgi I, Fontana E, Freri E, Marini C, Toraldo A, Specchio N, Veggiotti P, Vigevano F, Guerrini R, Guzzetta F, Dravet C (2011) Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients. Epilepsia. 52 (2): 386-392. doi.org/10.1111/j.1528-1167.2010.02925.x.
47. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O (1998) Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 39 (5): 508-512. doi.org/10.1111/j.1528-1157.1998.tb01413.x.
48. Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, Dulac O (2002) Efficacité et tolérance à long terme du stiripentol dans le traitement de l'épilepsie myoclonique sévère du nourrisson (syndrome de Dravet). Archives de Pédiatrie. 9 (11): 1120-1127. doi: 10.1016/s0929-693x(02)00090-8.
49. Tassinari CA, Dravet C, Roger J, Cano JP; Gastaut H (1972) Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. epilepsia. 13 (3): 421-435. doi.org/10.1111/j.1528-1157.1972.tb04582.x.
50. Touw M (1981) The religious and medicinal uses of cannabis in China, India and Tibet. Journal of Psychoactive Drugs. 13 (1): 23-34. doi.org/10.1080/02791072.1981.10471447.
51. Zuardi AW (2006) History of cannabis as a medicine: A review. Brazilian Journal of Psychiatry. 28 (2): 153-157. doi:10.1590/S1516-44462006000200015.
52. Aldrich M (1997) History of therapeutic cannabis. In: Mathre ML ed. Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana. Jefferson, NC, London: Mc Farland & Co. ISBN: 0-7964-0361-6.
53. O'Shaughnessy WB (1843) On the preparations of the Indian hemp, or Gunjah: cannabis indica their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Provincial Medical Journal and Retrospect of the Medical Sciences. 5 (123): 363-9. PMC2490264.
54. Crocq MA (2020) History of cannabis and the endocannabinoid system. Dialogues in Clinical Neurosciences. 22 (3): 223-228. doi.org/10.31887/DCNS.2020.22.3/mcrocq.
55. Mead A (2019) Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Frontiers in Plant Science. 10: 697. doi.org/10.3389/fpls.2019.00697.
56. U.S. Food and Drug Administration (FDA) News release (2018) [Internet] FDA approves first drug comprised of an active ingredient derived from Marijuana to treat rare, severe forms of epilepsy. [August 2021].
57. Smith PF (2004) GW-1000. GW Pharmaceuticals. Current Opinion in Investigational Drugs. 5 (7): 748-754. PMID:15298072.
58. Sharma P, Murthy P, Bharath MM (2012) Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iranian Journal of Psychiatry. 7 (4): 149-156. PMID:23408483.
59. Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsi Y, Navarro P, Etxebarria N, Usobiagal A (2016) Evolution of the cannabinoid and terpene content during the growth of cannabis sativa plants from different chemotypes. Journal of Natural Products. 79 (2): 324-331. doi.org/10.1021/acs.jnatprod.5b00949.
60. Wong SS, Wilens TE (2017) Medical cannabinoids in children and adolescents: A systematic review. Pediatrics. 140 (5): e20171818. doi.org/10.1542/peds.2017-1818.
61. Russo EB, Russo EB (2002) Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic potential. (1st ed.) Routledge; New York. ISBN: 9780203479506. doi.org/10.4324/9780203479506.
62. Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L (2018) *Cannabis sativa L.* and nonpsychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer. BioMed Research International. 2018. ID 1691428. doi.org/10.1155/2018/1691428.
63. Wilfong A, Cances C, Cross JH, Devinsky O, Marsh E (2018) Cannabidiol (CBD) reduces seizure frequency in patients with Dravet syndrome who had no response to prior medications: Subgroup analysis of phase 3 study GWPCARE1. American Epilepsy Society. November 6, 2018.

64. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 12 (4): 825-836. doi.org/10.1007/s13311-015-0387-1.
65. Accessdata.fda.gov (2018) Epidiolex prescribing information. [online] available at: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf> [Accessed 20 August 2021].
66. Vermersch P (2011) Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. Expert Review of Neurotherapeutics. 11 (4S): 15-19. doi.org/10.1586/ern.11.27.
67. Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, Jones N, Bazelot M, Williams CM, McNeish AJ (2019) Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia. 60 (2): 303-314. doi.org/10.1111/epi.14629.
68. Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R (1982) Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. European Journal of Pharmacology. 83 (3-4): 293-298. doi.org/10.1016/0014-2999(82)90264-3.
69. Kaplan JS, Stella N, Catterall WA, Westenbroek RE (2017) Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proceedings of the National Academy of Sciences of the United States of America. 114 (42): 11229-11234. doi.org/10.1073/pnas.1711351114.
70. Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, Saneto RP, Checketts D, Dunayevich E, Knappertz V (2020) GWPCARE2 Study Group. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: A randomized clinical trial. JAMA Neurology. 77 (5): 613-621. doi.org/10.1001/jamaneurol.2020.0073.
71. Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, Cannabidiol in Dravet Syndrome Study Group (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. The New England Journal of Medicine. 376 (21): 2011-2020. doi.org/10.1056/NEJMoa1611618.
72. Koo CM, Kim SH, Lee JS,Park BJ, Lee HK, Kim HD, Kang HC (2020) Cannabidiol for treating Lennox-Gastaut syndrome and Dravet syndrome in Korea. Journal of Korean Medical Science. 35 (50): e427. doi.org/10.3346/jkms.2020.35.e427.
73. Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood, SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group (2018) Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. The New England Journal of Medicine. 378 (20): 1888-1897. doi.org/10.1056/NEJMoa1714631.
74. Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, Checketts D, Roberts C (2019) Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 60 (3): 419-428. doi.org/10.1111/epi.14670.
75. Brodie JS, Di Marzo V, Guy GW (2015) Polypharmacology shakes hands with complex aetiopathology. Trends in Pharmacological Sciences. 36 (12): 802-821. doi.org/10.1016/j.tips.2015.08.010.
76. Seeman P (2016) Cannabidiol is a partial agonist at dopamine D2 High receptors, predicting its antipsychotic clinical dose. Translational Psychiatry. 6 (10): e920. doi.org/10.1038/tp.2016.195.
77. Russo EB, Burnett A, Hall B, Parker KK (2005) Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical Research. 30 (8): 1037-1043. doi.org/10.1007/s11064-005-6978-1.
78. Morano A, Fanella M, Albini M, Cifelli P, Palma E, Giallonardo AT, Di Bonaventura C (2020) Cannabinoids in the treatment of epilepsy: current status and future prospects. Neuropsychiatric Disease and Treatment. 16: 381-396. doi.org/10.2147/NDT.S203782.
79. Muller C, Morales P, Reggio PH (2019) Cannabinoid ligands targeting TRP channels. Frontiers in Molecular Neurosciences. 11: 487. doi.org/10.3389/fnmol.2018.00487.
80. Zendulka O, Dovrtělová G, Nosková K, Turjap M, Šulcová A, Hanuš L, Juřica J (2016) Cannabinoids and cytochrome P450 interactions. Current Drug Metabolism. 17 (3): 206-226. doi.org/10.2174/1389200217666151210142051.
81. Deutsch DG (2016) A personal retrospective: elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs). Frontiers in Pharmacology. 7: 370. doi.org/10.3389/fphar.2016.00370.
82. Galaj E, Xi ZX (2019) Potential of cannabinoid receptor ligands as treatment for substance use disorders. CNS Drugs. 33 (10): 1001-1030. doi.org/10.1007/s40263-019-00664-w.

83. Carrier EJ, Auchampach JA, Hillard CJ (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proceedings of the National Academy of Sciences of the United States of America. 103 (20): 7895-7900. doi.org/10.1073/pnas.0511232103.
84. Castillo A, Tolón MR, Fernández-Ruiz, Romero J, Martinez-Orgado J (2010) The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiology of Disease. 37 (2): 434-440. doi.org/10.1016/j.nbd.2009.10.023.
85. Hind WH, England TJ, O'Sullivan SE (2016) Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors. British Journal of Pharmacology. 173 (5): 815-825. doi.org/10.1111/bph.13368.
86. Bazelot M, Whalley B (2016) Investigating the involvement of GPR55 signaling in the antiepileptic effects of cannabidiol (P5.244). Neurology. 86 (16S) P5.244.
87. Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ (2018) Inhibitory effects of cannabidiol on voltage-dependent sodium currents. The Journal of Biological Chemistry. 293 (43): 16546-16558. doi.org/10.1074/jbc.RA118.004929.
88. Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg's Archives of Pharmacology. 372 (5): 354-361. doi.org/10.1007/s00210-006-0033-x.
89. Millar SA, Stone NL, Yates AS, O'Sullivan SE (2018) A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology. 9: 1365. doi.org/10.3389/fphar.2018.01365.
90. Kis B, Ifrim FC, Buda V, Avram S, Pavel IZ, Antal D, Paunescu V, Dehelean CA, Ardelean F, Diaconeasa Z, Soica C, Danciu C (2019) Cannabidiol-from plant to human body: A promising bioactive molecule with multi-target effects in cancer. International Journal of Molecular Sciences. 20 (23): E5905. doi.org/10.3390/ijms20235905.
91. Johannessen SI, Landmark CJ (2010) Antiepileptic drug interactions - principles and clinical implications. Current Neuropharmacology. 8 (3): 254-267. doi.org/10.2174/157015910792246254.
92. Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program (2017) Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 58 (9): 1586-1592. doi.org/10.1111/epi.13852.
93. Iffland K, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research. 2 (1): 139-154. doi.org/10.1089/can.2016.0034.
94. Lattanzi S, Zaccara G, Russo E, La Neve A, Lodi MAM, Striano P (2021) Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome. Expert Review of Neurotheapeutics. 21 (1): 99-110. doi.org/10.1080/14737175.2021.1834383.
95. Franco V, Perucca E (2019) Pharmacological and therapeutic properties of cannabidiol for epilepsy. Drugs. 79 (13): 1435-1454. doi.org/10.1007/s40265-019-01171-4.
96. Lattanzi S, Trinka E, Striano P, Rocchi C, Salvemini S, Silvestrini M, Brigo F (2021) Highly purified cannabidiol for epilepsy treatment: a systematic review of epileptic conditions beyond Dravet syndrome and Lennox-Gastaut syndrome. CNS Drugs. 35 (3): 265-281. doi.org/10.1007/s40263-021-00807-y.
97. Chang BS (2018) Cannabidiol and serum antiepileptic drug levels: the ABCs of CBD with AEDs. Epilepsy Currents. 18 (1): 33-34. doi.org/10.5698/1535-7597.18.1.33.
98. Abu-Sawwa R, Scutt B, Park Y (2020) Emerging use of epidiolex (Cannabidiol) in epilepsy. The Journal of Pediatric Pharmacology and Therapeutics. 25 (6): 485-499. doi.org/10.5863/1551-6776-25.6.48.
99. Epidiolex prices, coupons and patient assistance programs - Drugs.com. https://www.drugs.com/price-guide/epidiolex. Accessed November 2, 2021.